Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 7, 2003, Pages 3202-3211

  Peeters, Robin P ^a   Wouters, Pieter J ^a   Kaptein, Ellen ^a   Van Toor, Hans ^a   Visser, Theo J ^a   Van Den Berghe, Greet ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; INSULIN; IODOTHYRONINE DEIODINASE 1; IODOTHYRONINE DEIODINASE 2; IODOTHYRONINE DEIODINASE 3; THYROID HORMONE; THYROTROPIN; THYROXINE; THYROXINE DEIODINASE; UNCLASSIFIED DRUG; UREA;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN INJURY; CELL HYPOXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL ILLNESS; DEIODINATION; DIALYSIS; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; INFLAMMATION; INOTROPISM; INSULIN TREATMENT; INTENSIVE CARE; LIVER; MAJOR CLINICAL STUDY; MALE; MUSCLE BIOPSY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKELETAL MUSCLE; THYROID HORMONE BLOOD LEVEL; THYROID HORMONE RELEASE; THYROXINE BLOOD LEVEL; TISSUE METABOLISM; TISSUE PERFUSION; TISSUE SPECIFICITY;

AGED; AGED, 80 AND OVER; BIOPSY; CRITICAL ILLNESS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MIDDLE AGED; MUSCLE, SKELETAL; REGRESSION ANALYSIS; THYROID HORMONES; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0037961036     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-022013     Document Type: Article

References (32)

1. Van den Berghe G 2002 Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 23:370-391
2. Ligtenberg JJ, Girbes AR, Beentjes JA, Tulleken JE, van der Werf TS, Zijlstra JG 2001 Hormones in the critically ill patient: to intervene or not to intervene? Intensive Care Med 27:1567-1577
3. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R 2002 The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 56:655-669
4. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ 1999 Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785-792
5. Bone RC, Fisher Jr CJ, Clemmer TP, Slotman G J, Metz CA, Balk RA 1987 A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658
6. Slotman GJ, Fisher Jr CJ, Bone RC, Clemmer TP, Metz CA 1993 Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 21:191-195
7. Brent GA, Hershman JM 1986 Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 63:1-8
8. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R 2001 Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359-1367
9. Van den Berghe G 1999 Growth hormone secretagogues in critical illness. Horm Res 51(S3):21-28
10. Docter R, Krenning EP, de Jong M, Hennemann G 1993 The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) 39:499-518
11. Leonard JL, Koehrle J 2000 Intracellular pathways of iodothyronine metabolism. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the thyroid: a fundamental and clinical text. Philadelphia: Lippincott, Williams &. Wilkins; 136-173, ed 8
12. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89
13. Kaptein EM, Robinson WJ, Grieb DA, Nicoloff JT 1982 Peripheral serum thyroxine, triiodothyronine and reverse triiodothyronine kinetics in the low thyroxine state of acute nonthyroidal illnesses. A noncompartmental analysis. J Clin Invest 69:526-535
14. Faber J, Thomsen HF, Lumholtz IB, Kirkegaard C, Siersbaek-Nielsen K, Friis T 1981 Kinetic studies of thyroxine, 3, 5, 3′-triiodothyronine, 3, 3, 5′-triiodothyronine, 3′, 5′-diiodothyronine, 3, 3′-diiodothyronine, and 3′-monoiodothyronine in patients with liver cirrhosis. J Clin Endocrinol Metab 53:978-984
15. Kaptein EM, Feinstein EI, Nicoloff JT, Massry SG 1983 Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. J Clin Endocrinol Metab 57:181-189
16. Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ 2001 Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 224:451-476
17. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, Fishman SJ, Larsen PR 2000 Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343:185-189
18. Toyoda N, Kaptein E, Berry MJ, Harney JW, Larsen PR, Visser TJ 1997 Structure-activity relationships for thyroid hormone deiodination by mammalian type I iodothyronine deiodinases. Endocrinology 138:213-219
19. Mol JA, Visser TJ 1985 Synthesis and some properties of sulfate esters and sulfamates of iodothyronines. Endocrinology 117:1-7
20. Mol JA, Docter R, Kaptein E, Jansen G, Hennemann G, Visser TJ 1984 Inactivation and affinity-labeling of rat liver iodothyronine deiodinase with N-bromoacetyl-3, 3′, 5-triiodothyronine. Biochem Biophys Res Commun 124:475-483
21. Mendel CM, Frost PH, Kunitake ST, Cavalieri RR 1987 Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 65:1259-1264
22. Visser TJ, Docter R, Hennemann G 1977 Radioimmunoassay of reverse triiodothyronine. J Endocrinol 73:395-396
23. Schoenmakers CH, Pigmans IG, Visser TJ 1992 Species differences in liver type I iodothyronine deiodinase. Biochim Biophys Acta 1121:160-166
24. Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, De Herder WW, den Hollander JC, Krenning EP, Visser TJ 1998 Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab 83:2868-2874
25. Salvatore D, Bartha T, Harney JW, Larsen PR 1996 Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 137:3308-3315
26. Wortsman J, Premachandra BN, Chopra IJ, Murphy JE 1987 Hypothyroxinemia in cardiac arrest. Arch Intern Med 147:245-248
27. Berry MJ, Kates AL, Larsen PR 1990 Thyroid hormone regulates type I deiodinase messenger RNA in rat liver. Mol Endocrinol 45:743-748
28. Kester MH, Kaptein E, Van Dijk CH, Roest TJ, Tibboel D, Coughtrie MW, Visser TJ 2002 Characterization of iodothyronine sulfatase activities in human and rat liver and placenta. Endocrinology 143:814-819
29. Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR 2000 Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. Endocrinology 1413:1127-1135
30. Huang TS, Chopra IJ, Boado R, Soloman DH, Chua Teco GN 1988 Thyroxine inner ring monodeiodinating activity in fetal tissues of the rat. Pediatr Res 23:196-199
31. Van den Berghe G, de Zegher F 1996 Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 24:1580-1590
32. Kohrle J, Muller MJ, Kodding R, Seitz HJ, Hesch RD 1982 pH-dependency of iodothyronine metabolism in isolated perfused rat liver. Biochem J 202:667-675